Pharmaceutical - Valeant Pharmaceuticals

Filter

Current filters:

Valeant Pharmaceuticals

Popular Filters

1 to 25 of 47 results

Valeant takes Allergan's 'false and misleading statements' to Quebec and US financial regulators

Valeant takes Allergan's 'false and misleading statements' to Quebec and US financial regulators

22-07-2014

In the latest in an ongoing takeover attempt of Allergan by Valeant, Valeant has contacted financial…

AllerganBausch & LombCanadaFinancialPharmaceuticalRegulationUSAValeant Pharmaceuticals

Allergan rejects Valeant’s latest bid

Allergan rejects Valeant’s latest bid

24-06-2014

Botox maker Allergan has announced that its Board of Directors has unanimously determined that Valeant…

AllerganBusiness FinanceBusiness FinanceEconomicsFinanceMergers & AcquisitionsPharmaceuticalStock marketUSAValeant Pharmaceuticals

US FDA grants Valeant approval for Jublia NDA

US FDA grants Valeant approval for Jublia NDA

09-06-2014

Canadian drugmaker Valeant Pharmaceuticals International’s US subsidiary has received approval from…

CanadaDermatologicalsefinaconazoleJubliaPharmaceuticalRegulationUS Food and Drug AdministrationValeant Pharmaceuticals

Allergan warns shareholders to take no action ahead of Valeant calling ‘special meeting’

Allergan warns shareholders to take no action ahead of Valeant calling ‘special meeting’

03-06-2014

Takeover target USA-based Allergan has responded to action taken by Canadian drugmaker Valeant Pharmaceuticals…

AllerganBusiness FinanceMergers & AcquisitionsPharmaceuticalUSAValeant PharmaceuticalsValeant Pharmaceuticals International

Valeant ups offer for Allergan as target publishes attack on its business model

Valeant ups offer for Allergan as target publishes attack on its business model

28-05-2014

Canadian drugmaker Valeant Pharmaceuticals International has today upped its offer for USA-based Allergan…

AllerganBusiness FinanceBusiness FinanceCanadaMergers & AcquisitionsPharmaceuticalUSAValeant PharmaceuticalsValeant Pharmaceuticals International

Valeant Pharma to sell filler and toxin assets to Nestle for $1.4 billion

Valeant Pharma to sell filler and toxin assets to Nestle for $1.4 billion

28-05-2014

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International has entered into an agreement to…

DermatologicalsGaldermaMergers & AcquisitionsNestlePharmaceuticalValeant Pharmaceuticals

Allergan board totally rejects Valeant’s $46 billion bid

Allergan board totally rejects Valeant’s $46 billion bid

13-05-2014

USA-based Allergan said yesterday that its board of directors has unanimously rejected the $46 billion…

AllerganMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

Takeover target Allergen reports strong 1st-qtr sales growth

07-05-2014

US drugmaker Allergan reported a strong set of first-quarter 2014 financial results, with global sales…

AllerganFinancialMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

Allergan adopts stockholder rights plan

23-04-2014

USA-based Allergan, the subject of a hostile takeover bid from Canada’s Valeant Pharmaceuticals reported…

AllerganFinancialMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

Valeant joins with hedge fund in $45.6 billion unsolicited bid for Allergan

22-04-2014

Canada’s Valeant Pharmaceuticals International, never shy to go for hostile takeover moves, says it…

AllerganMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

US FDA approves NDA from Actavis and Valeant

US FDA approves NDA from Actavis and Valeant

26-03-2014

US generics major Actavis and Canada’s Valeant Pharmaceuticals said that the US Food and Drug Administration…

ActavisCanadaGenericsMetronidazolePharmaceuticalRegulationUSAValeant PharmaceuticalsWomen's Health

Valeant spending $475 million to boost dermatology portfolio

Valeant spending $475 million to boost dermatology portfolio

03-02-2014

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International has entered into a definitive agreement…

DermatologicalsMergers & AcquisitionsPharmaceuticalPreCision DermatologyValeant Pharmaceuticals

Valeant agrees $142.5 million settlement with Anacor

28-10-2013

Anacor Pharmaceuticals says it has entered into a $142,5 million settlement agreement with Canada-based…

Anacor PharmaceuticalsFinancialLegalNorth AmericaPharmaceuticalValeant Pharmaceuticals

Anacor Pharma awarded $100 million damages

18-10-2013

Anacor Pharmaceuticals says that the arbitrator appointed to resolve its dispute with Canada-based Valeant…

Anacor PharmaceuticalsLegalNorth AmericaPharmaceuticalValeant Pharmaceuticals

Valeant confirms plan to acquire Bausch & Lomb in a $8.7 billion transaction

28-05-2013

Following speculation ahead of the extended holiday weekend, acquisitive Canadian drugmaker Valeant Pharmaceuticals…

Bausch & LombMergers & AcquisitionsOphthalmicsPharmaceuticalValeant Pharmaceuticals

Merz Pharma enters bidding war for Obagi; Ferro sells pharma unit

02-04-2013

German family-owned firm Merz Pharma has written to the board of director of Obagi Medical Products outlining…

Ferro GroupGenericsMergers & AcquisitionsMerz PharmaceuticalsObagi Medical ProductsPfanstiehl LaboratoriesPharmaceuticalValeant Pharmaceuticals

Valeant to acquire Obagi Medical for around $344 million

20-03-2013

Canada-based Valeant Pharmaceuticals International (TSX: VRX) is on the acquisition trail again, announcing…

DermatologicalsMergers & AcquisitionsObagi Medical ProductsPharmaceuticalValeant Pharmaceuticals

Valeant Pharma buys US rights to Eisai's Targretin for $65 million upfront

21-02-2013

Canada's Valeant Pharmaceuticals International (TSX: VRX) says that it has acquired US rights for Targretin…

EisaiLicensingNorth AmericaOncologyPharmaceuticalTargretinValeant Pharmaceuticals

1 to 25 of 47 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top